US0396971071
© Globe Newswire
08.01.2026
ARDX
LISTED
NASDAQ
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
News Preview
Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 ...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2025
ARDX
LISTED
NASDAQ
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
News Preview
WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data, including results from the first real-world study...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ARDX
LISTED
NASDAQ
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
News Preview
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbu...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
28.10.2025
ARDX
LISTED
NASDAQ
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
News Preview
IBSRELA patients reported treatment satisfaction in real-world survey...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
13.10.2025
ARDX
LISTED
NASDAQ
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
News Preview
Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.10.2025
ARDX
LISTED
NASDAQ
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
News Preview
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective No...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.06.2025
ARDX
LISTED
NASDAQ
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
News Preview
WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Kelliher, formerly Executive Vice President, Corporate Development and S...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2025
ARDX
LISTED
NASDAQ
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
News Preview
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will participate in a fireside chat at the Jeffe...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.05.2025
ARDX
LISTED
NASDAQ
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
News Preview
Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress Analysis of IBS in America 2024 Real-World Survey Demonstrates that severity of IBS-C correlates with financial hardship and distress...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.04.2025
ARDX
LISTED
NASDAQ
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
News Preview
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company’s first-in-class retain...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.04.2025
ARDX
LISTED
NASDAQ
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
News Preview
Conference call scheduled for 4:30 p.m. Eastern Time Conference call scheduled for 4:30 p.m. Eastern Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.03.2025
ARDX
LISTED
NASDAQ
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
News Preview
Award established to recognize leaders in the field of chronic kidney disease advocacy Award established to recognize leaders in the field of chronic kidney disease advocacy...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
26.02.2025
ARDX
LISTED
NASDAQ
Tenapanor Approved in China for Hyperphosphatemia
News Preview
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval Ardelyx to receive $5 million milestone payment from Fosun Pharma following approval...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ARDX
LISTED
NASDAQ
Ardelyx to Participate in Upcoming Investor Conferences
News Preview
WALTHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ARDX
LISTED
NASDAQ
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
News Preview
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
ARDX
LISTED
NASDAQ
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
News Preview
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on M...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.01.2025
ARDX
LISTED
NASDAQ
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
News Preview
Conference call scheduled for 8:00 a.m. Eastern Time Conference call scheduled for 8:00 a.m. Eastern Time...
Themefolio
Profiler
Peergroup
© Globe Newswire
13.01.2025
ARDX
LISTED
NASDAQ
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
News Preview
Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited)...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.11.2024
ARDX
LISTED
NASDAQ
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
News Preview
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief C...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2024
ARDX
LISTED
NASDAQ
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
News Preview
Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk Inclusion of oral-only phosphate-lowering therapies in the ESRD PPS will put dialysis patients’ health at risk...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2024
ARDX
LISTED
NASDAQ
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
News Preview
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, Justin Renz, Chief Financial and Operations...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2024
ARDX
LISTED
NASDAQ
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
News Preview
Deadline to submit nominations is January 31, 2025 Deadline to submit nominations is January 31, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
ARDX
LISTED
NASDAQ
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and reminds investors of the October 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & F...
Themefolio
Profiler
Peergroup
© BusinessWire
12.10.2024
ARDX
LISTED
NASDAQ
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers and acquirers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024, both dates inclusive (the “Class Period”). Ardelyx describes itself as a “biotechnology company focused on developing...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2024
ARDX
LISTED
NASDAQ
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
News Preview
WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the recent publication of a review article, titled “Review of the Patient Burden a...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ARDX
LISTED
NASDAQ
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Nano Ardelyx, Inc. (ARDX) Investors
News Preview
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) securities during the period of October 31, 2023 to July 1, 2024, inclusive (“the Class Period”). Investors h...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2024
ARDX
LISTED
NASDAQ
Shareholder Rights Law Firm Robbins LLP Urges ARDX Stockholders with Large Losses to Contact the Firm for Information About the Ardelyx, Inc. Lawsuit
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024. Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients...
Themefolio
Profiler
Peergroup
© BusinessWire
01.09.2024
ARDX
LISTED
NASDAQ
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violat...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
ARDX
LISTED
NASDAQ
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violat...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2024
ARDX
LISTED
NASDAQ
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024. Ardelyx is a biotechnology company focused on developing and commercializing therapies for, among other things, patients...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
ARDX
LISTED
NASDAQ
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investor...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
ARDX
LISTED
NASDAQ
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
News Preview
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and reminds investors of the October 15, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi &...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
ARDX
LISTED
NASDAQ
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Ardelyx, Inc. (NASDAQ: ARDX) between October 31, 2023 and July 1, 2024. Ardelyx describes itself as a “biotechnology company focused on developing and commercializing therapies for, among other things, p...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.07.2024
ARDX
LISTED
NASDAQ
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
News Preview
WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
ARDX
LISTED
NASDAQ
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
News Preview
Lawsuit challenges CMS’s statutory overreach in its determination to include oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.07.2024
ARDX
LISTED
NASDAQ
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
News Preview
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
ARDX
LISTED
NASDAQ
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
News Preview
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with con...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.05.2024
ARDX
LISTED
NASDAQ
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
News Preview
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operatio...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.05.2024
ARDX
LISTED
NASDAQ
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
News Preview
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapan...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2024
ARDX
LISTED
NASDAQ
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
News Preview
WALTHAM, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of XPHOZAH® (tenapan...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2024
ARDX
LISTED
NASDAQ
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
News Preview
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting IBSRELA® (tenapanor) will be presented at the 2024...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
